Related Experiment Video
Updated: Jun 16, 2026

SA-β-Galactosidase-Based Screening Assay for the Identification of Senotherapeutic Drugs
Published on: June 28, 2019
Senolytic compounds reduce epigenetic age of blood samples in vitro
Vithurithra Tharmapalan1,2, Miriam Du Marchie Sarvaas1,2, Michael Bleichert1,2
1Institute for Stem Cell Biology, RWTH Aachen University Medical School, 52074, Aachen, Germany.
Abstract:
Senolytic drugs raise the expectation that they can specifically eliminate a subset of senescent cells in a given tissue. In this study, we have exemplarily analyzed if a 3-day treatment of human blood samples in vitro would reduce age-associated biomarkers, with a particular focus on epigenetic age-predictions. Of eight tested compounds, JQ1, RG7112, nutlin-3a, and AMG232 reduced epigenetic age, indicating that this approach may be useful in drug screening for senolytic compounds.
Related Concept Videos
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism
Pharmacodynamics in Geriatric Patients: Effects of Age
The Effect of Aging on Tissues

